The US Food and Drug Administration (FDA) has proposed a new policy intended to modernise and improve the quality of mammography, which is used for breast cancer screening and diagnosis.

The first in more than two decades, these amendments require mammography facilities to provide patients and their healthcare professionals with details on breast density in order to enable more informed decision-making.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Mammography images of breasts with higher fibroglandular tissue versus fatty tissue (dense breasts) could be tough to interpret due to unclear signs of cancer and lower sensitivity.

The US regulator has proposed specific language to explain the effect of breast density on the mammography’s accuracy.

“As part of our overall commitment to protecting the health of women, we’re proposing new policies to modernise our oversight of mammography services.”

In addition, the new rules aim to provide healthcare professionals with more information through three additional categories for mammogram evaluations.

FDA commissioner Scott Gottlieb said: “As part of our overall commitment to protecting the health of women, we’re proposing new policies to modernise our oversight of mammography services by capitalising on a number of important advances in mammography, like the increased use of 3D digital screening tools and the need for more uniform breast density reporting.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The amendments also involve notifications to patients and their healthcare professionals about mammography facilities’ quality standards and components used.

The FDA has also proposed better record-keeping to reduce information loss and improve access to and transfer of patient records.

The National Cancer Institute (NCI) statistics show that more than 260,000 women were diagnosed with breast cancer last year, and over 40,920 women died from the illness.

The disease is the second leading cause of death in women and may also affect men of any age. Mammography is considered as an important method to detect breast cancer.

A recent study by Yale School of Public Health and School of Medicine found that state breast density notification laws that require reporting of mammogram results are linked to more screening and cancer detection rates.

Moreover, some states also mandate recommendations for women with dense breasts to get further screening tests such as ultrasound and MRI.

It was observed that laws recommending further tests had more rates of breast ultrasound and cancer detection, compared with notifications that only included information about breast density.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact